143790-25-4

Basic information

• Product Name: 1-[4-(4-Fluoro-phenyl)-4-oxo-butyl]-piperidine-3-carboxylic acid
• CAS NO: 143790-25-4
• Molecular Weight: 293.338
• Mol File: 143790-25-4.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 1-[4-(4-Fluoro-phenyl)-4-oxo-butyl]-piperidine-3-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[4-(4-Fluoro-phenyl)-4-oxo-butyl]-piperidine-3-carboxylic acid(143790-25-4)
• EPA Substance Registry System: 1-[4-(4-Fluoro-phenyl)-4-oxo-butyl]-piperidine-3-carboxylic acid(143790-25-4)

Safety Data

• Hazardous Substances Data: 143790-25-4(Hazardous Substances Data)

Upstream product

• 40132-01-2 1-(4-fluorophenyl)-4-bromo-1-butanone 
• 71962-74-8 Ethyl nipecotate 

Relevant articles and documents

Structure-Activity Studies on Benzhydrol-Containing Nipecotic Acid and Guvacine Derivatives as Potent, Orally-Active Inhibitors of GABA Uptake

The introduction of lipophilic groups onto the ring nitrogen of nipecotic acid and guvacine, two known GABA uptake inhibitors, afforded potent, orally-active anticonvulsant drugs.A series of compounds is reported which explores the structure-activity relationships (SAR) in this series.Among the areas explored: side-chain SAR (aromatic-, heterocyclic-, and tricyclic-containing side chains) and modifications to the tetrahydropyridine ring.The benzhydrol ether-containing side chains afforded the most potent compounds with several exhibiting in vitro IC50 values for GABA uptake of 1 μM (including 5, Table I; 37, 43, Table IV; and 44, Table V).Compound 44 was selected for extensive evaluation and subsequently progressed to Phase 1 clinical trials with severe adverse effects seen after single dose administration to humans.